SAGE: חוב כולל להון Sage Therapeutics

The financial price visualization for Sage Therapeutics, Inc. (SAGE) demonstrates a debt-to-equity ratio of 0.03. The business relies on the development of antidepressants, for which demand is independent of economic cycles and seasonality. High brand authority among scientists is coupled with a pragmatic outlook from shareholders. However, geopolitical tensions and sanctions are seriously hindering global testing and the logistics of biomaterials.

Despite Zurzuvae's patent exclusivity, insurance reimbursement barriers are limiting revenue, making debt load control critical for Sage Therapeutics, Inc. (SAGE). The current total debt-to-equity ratio of 0.03 measures the proportion of borrowed funds within the balance sheet structure, allowing investors to assess financial stability and default risk by analyzing the trends on this chart.